Bayview Legacy, LLC

10% owner Bayview Legacy, LLC sells 70,000 shares (70.0K shares) for $2,443,432.56 via 10b5-1 plan at AIP

Bayview Legacy, LLC completed 2 separate sales totaling 70,000 shares for $2,443,432.56 on 2026-06-08 under a pre-arranged 10b5-1 trading plan, reducing holdings from 8,999,071 shares to 8,929,071 shares (-0.8%). The transaction is scheduled, not discretionary. At the same-ticker level, the insider's 5 prior trades at AIP show mixed post-transaction performance (returns ranging from -18.0% to +77.3% over 90 days), indicating no clear pattern of consistent timing accuracy. The company reported negative net income ($-7,959,000.00) in its latest quarter despite revenue of $22,936,000.00 and annual growth of +22.3%, suggesting operational challenges beneath top-line expansion. The 10b5-1 structure removes discretionary intent from this filing; the sale reflects a pre-planned execution rather than a contemporaneous market signal.

10% owner LLC Bayview Legacy sold 70,000 shares of Arteris for ~$2.2M, continuing a pattern of repeated sales.

LLC Bayview Legacy, a significant institutional holder with over ten percent beneficial ownership in Arteris, completed its 18th open-market sale in the past three years, disposing of 70,000 shares. This latest transaction represents continued portfolio activity at a time when the stock has rallied sharply and now trades at its 52-week high—a period that has typically preceded flat or declining performance in this holder's prior exits. Reviewing the fund's recent selling history at Arteris shows mixed timing: two of its four prior sales at this ticker were well-timed exits that preceded declines, while the other two saw the stock rise afterward. The company itself remains unprofitable despite revenue growth, trading at a valuation that reflects significant losses; Arteris is burning cash and has yet to reach breakeven. For a passive institutional holder managing a large block, rotating out shares at elevated prices is routine portfolio management rather than a contrarian bet. The real test will be whether the stock's recent momentum persists or reverts—a question this filing alone does not answer, but one that the holder may be hedging by taking profits at current levels.

Bayview Legacy LLC sold 70,000 shares of AIP at $19.04 on 2026-04-08 (current price $19.56); stock near 52-week high after +28.3% 30-day surge.

Bayview Legacy, LLC sold 70,000 shares (0.8% of pre-transaction holdings) near the company's 52-week high of $19.67, with the stock up 28.3% over the prior 30 days. At the time of sale on 2026-04-08, Arteris was trading at $19.04, just 0.6% below its 52-week high. The sale reduced holdings from 9.19M to 9.12M shares, leaving the insider with a substantial ownership stake. Notably, Arteris remains unprofitable (full-year net income negative, most recent quarterly net income -$9.0M) despite posting 22.3% annual revenue growth. The insider's same-ticker history shows a mixed timing pattern: two of three prior sales at AIP subsequently declined (well-timed at 90-day mark), though one preceding October 2025 sale saw the stock rise 18.9% thereafter. This latest sale occurred following a sharp monthly rally and near peak valuation.

10% owner Bayview Legacy LLC sells 130,000 shares of Arteris (AIP) for $2,264,640 amid 121.6% gain; stock at 52-week high

Bayview Legacy, LLC, a 10% owner, executed 2 separate sales totaling 130,000 shares for $2,264,640.00 at an average price of $17.42 across December 5–8, 2025. The stock has appreciated 121.6% over 90 days and is currently trading at $19.19, matching its 52-week high, representing a 32.5% gain in the past 30 days alone. The company remains unprofitable with net income of $-8,991,000.00 in the latest quarter, despite 7.6% annual revenue growth. The sales reduced holdings by 1.4% (from 9.60M to 9.47M shares), a modest reduction for a 10% holder, yet the timing occurs at peak valuations after a sustained rally rather than during periods of weakness.

Bayview Legacy, LLC sold 100,000 shares of Arteris at $13.10 on 2025-10-06; retains 9,739,071 shares (9.74M shares)

Bayview Legacy, LLC reduced its stake by 100,000 shares (-1.0% vs pre-transaction holdings) while maintaining substantial ownership of 9,739,071 shares. The transaction occurred at $13.10 per share as the stock trades near its 52-week high of $13.58, reflecting a 57.0% gain over 30 days and 46.3% over 90 days. Arteris remains unprofitable with net income of $-9,130,000.00 on revenue of $16,502,000.00 for the latest quarter, though the company posted 7.6% annual revenue growth. The sale represents a modest reduction from the 10% owner during a period of strong stock appreciation but comes against an ongoing unprofitable operating backdrop.